TiumBio Co., Ltd. (KOSDAQ:321550)
South Korea · Delayed Price · Currency is KRW 12,900
+990 (8.31%)
At close: Apr 1, 2026
TiumBio Revenue
In the year 2025, TiumBio had annual revenue of 12.29B KRW with 80.92% growth. TiumBio had revenue of 4.45B in the quarter ending December 31, 2025, with 200.09% growth.
Revenue
12.29B
Revenue Growth
+80.92%
P/S Ratio
26.05
Revenue / Employee
n/a
Employees
n/a
Market Cap
320.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.29B | 5.50B | 80.92% |
| Dec 31, 2024 | 6.79B | 1.89B | 38.65% |
| Dec 31, 2023 | 4.90B | -4.22B | -46.27% |
| Dec 31, 2022 | 9.12B | 9.06B | 15,952.75% |
| Dec 31, 2021 | 56.80M | -992.15M | -94.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 100.17B |
| NIBEC | 32.72B |
| Genome & Company | 24.59B |
| Prestige Biologics | 19.24B |
| S.Biomedics | 16.96B |
| Bio Solution | 15.20B |
| Kangstem Biotech | 3.57B |
| Y-Biologics | 2.91B |